Rare Disease Day 2024
It’s Rare Disease Day 2024! We’re always excited to see how glycobiology research impacts patient treatments and are proud to be...
Read moreIt’s Rare Disease Day 2024! We’re always excited to see how glycobiology research impacts patient treatments and are proud to be...
Read moreGlycan analysis poses significant challenges due to the intricate nature of glycan structures and their diverse compositions, making comprehensive...
Read moreLectenz Bio attended and sponsored the Society for Glycobiology 2023 Annual Meeting in Hawaii. VP of R&D Sean Wu presented our poster...
Read moreLectenz Bio has recently signed a distribution agreement with Labscoop, a U.S. life science distributor. This agreement will allow Labscoop to...
Read moreLectenz Bio has recently signed a distribution agreement with Apical Lab Corp., a Taiwanese life science distributor. This agreement will allow...
Read moreThe National Institutes of Health (NIH) National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio an SBIR Phase II to further...
Read moreThe National Institute of Health (NIH) Office of Research Infrastructure Programs (ORIP) awards Lectenz Bio an SBIR Fast-Track to develop N-glycan...
Read moreLectenz Bio has recently signed a distribution agreement with ZAGENO, a European life science distributor. This agreement will allow ZAGENO to...
Read moreCedarlane is now distributing Lectenz Bio products for Canadian customers. We are excited to have Cedarlane listing our catalog and look forward...
Read moreLectenz Bio has recently signed a distribution agreement with MBL Beijing Biotech Co., Ltd., a Chinese life science distributor. This agreement...
Read moreLectenz Bio has recently signed a distribution agreement with Scientist.com, a U.S. life science distributor. This agreement will allow...
Read moreLectenz Bio was excited to have CEO Lori Yang and VP of R&D Sean Wu present at the Common Fund GlycoScience Program!
Read more